A Study Of Personalized Molecular Markers To Transform Treatment Of High Grade Endometrial Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 19-005326
- Rochester, Minnesota: 19-005326
- Scottsdale/Phoenix, Arizona: 19-005326
Sponsor Protocol Number: 19-005326
About this study
The purpose of this study is to characterize a landscape of DNA alterations, RNA transcripts, and microbiome changes in resected tumors and body fluids of patients that have been diagnosed with aggressive endometrial cancer (Grade 3 and Type II) in order to identify molecular targets for which therapeutic drugs may exist.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Women age ≥ 18 years.
- Biopsy-proven high-grade endometrial cancer.
- Biopsy histology is Grade 3 endometrioid, serous, clear cell, poorly differentiated, or undifferentiated.
- Scheduled to undergo hysterectomy at Mayo Clinic.
- Willing to complete follow-up serial blood samples post-operatively.
- Willing and able to provide signed informed consent.
Exclusion Criteria:
- Biopsy histology is Grade 1 or Grade 2 endometrioid.
- Change in planned surgical procedure such that hysterectomy is not performed at Mayo Clinic.
- Tumor quantity or cell viability expected to not be sufficient for the study analyses.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Jacksonville, Fla.
Mayo Clinic principal investigator Matthew Robertson III, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Rochester, Minn.
Mayo Clinic principal investigator Gretchen Glaser, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Paul Magtibay, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available